01784nam a2200349Ia 4500001001200000003000600012005001700018007001400035008004100049040005600090043001200146074001900158086002300177110009800200245022200298246005000520260004200570300002800612336002600640337002700666338003100693500002600724504004100750533009400791500003500885500002500920650001900945650001700964650002900981776020401010776022001214ocm51932126OCoLC20180312141842.0he bmb024bbca030327s2002    dcu     bb   f000 0 eng d  aFPSbengcFPSdOCLCQdOCLCOdOCLCQdOCLCAdGPOdMvI  an-us---  a1019-B-01 (MF)0 aY 4.C 73/8:107-1401 aUnited States.bCongress.bHouse.bCommittee on Energy and Commerce.bSubcommittee on Health.10aExamining issues related to competition in the pharmaceutical marketplace :ba review of the FTC report, generic drug entry prior to patent expiration : hearing before ... 107th Congress, 2nd session, October 9, 2002.30aGeneric drug entry prior to patent expiration  aWashington, DC :bU.S. G.P.O.,c2002.  aiii, 142 pages ;c24 cm  atextbtxt2rdacontent  amicroformbh2rdamedia  amicrofichebhe2rdacarrier  a"Serial no. 107-140."  aIncludes bibliographical references.  aMicrofiche.bWashington :cSupt. of Docs., U.S. G.P.O.,d2003.e2 microfiches : negative.  aShipping list no.:2003-0144-M.  aCRDP Program record. 0aGeneric drugs. 0aCompetition. 0aPharmaceutical industry.08iOnline version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.tExamining issues related to competition in the pharmaceutical marketplacew(OCoLC)85278416808iPrint version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.tExamining issues related to competition in the pharmaceutical marketplacew(DLC) 2003387711w(OCoLC)51543393